Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Infection in Lung Transplant Recipients

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2023 Apr 24

PMID 37090036

Authors

Juan Chen

Qiqiang Liang

Shuo Ding

Yongshan Xu

Yanting Hu

Jingyu Chen

Man Huang

Affiliations

Soon will be listed here.

Abstract

Background: Experience of ceftazidime-avibactam (CAZ/AVI) for carbapenem-resistant (CRPA) infection in recipients after lung transplantation (LT) is relatively limited.

Methods: A retrospective observational study was conducted on lung transplant recipients receiving CAZ/AVI therapy for CRPA infection. The primary outcomes were the 14-day and 30-day mortality. The secondary outcomes were clinical cure and microbiological cure.

Results: Among 183 LT recipients, a total of 15 recipients with CRPA infection who received CAZ/AVI therapy were enrolled in this study. The mean age of recipients was 54 years and 73.3% of recipients were male. The median time from infection onset to initiation of CAZ/AVI treatment was 4 days (IQR, 3-7) and the mean duration of CAZ/AVI therapy was 10 days. CAZ/AVI was mainly administered as monotherapy in LT recipients (80%). Among these eligible recipients, 14-day and 30-day mortality were 6.7% and 13.3%, respectively. The clinical cure and microbiological cure rates of CAZ/AVI therapy were 53.3% and 60%, respectively. Three recipients (20%) experienced recurrent infection. In addition, the mean lengths of ICU stay and hospital stay were 24 days and 35 days, respectively, among LT recipients.

Conclusion: CAZ/AVI may be an alternative and promising regimen for CRPA eradiation in lung transplant recipients.

Citing Articles

Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.

Aldardeer N, Labban H, Alhuthil R, Aljahdali S, Alharbi M, Alharbi R BMC Infect Dis. 2024; 24(1):1455.

PMID: 39710682 PMC: 11663332. DOI: 10.1186/s12879-024-10365-5.

Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.

Narimisa N, Keshtkar A, Dadgar-Zankbar L, Bostanghadiri N, Far Y, Shahroodian S Front Microbiol. 2024; 15:1477836.

PMID: 39473844 PMC: 11520190. DOI: 10.3389/fmicb.2024.1477836.

Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study.

Li K, Li D, Dong H, Ren D, Gong D, Wang S Infect Drug Resist. 2024; 17:1281-1289.

PMID: 38566771 PMC: 10986624. DOI: 10.2147/IDR.S452805.

References

Rodriguez-Nunez O, Ripa M, Morata L, de la Calle C, Cardozo C, Feher C . Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018; 15:136-139. DOI: 10.1016/j.jgar.2018.07.010. View

Gill C, Aktab E, Alfouzan W, Bourassa L, Brink A, Burnham C . The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021; 40(12):2533-2541. PMC: 8590662. DOI: 10.1007/s10096-021-04308-0. View

Stone G, Newell P, Gasink L, Broadhurst H, Wardman A, Yates K . Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018; 73(9):2519-2523. DOI: 10.1093/jac/dky204. View

De Muynck B, Van Herck A, Sacreas A, Heigl T, Kaes J, Vanstapel A . Successful eradication improves outcomes after lung transplantation: a retrospective cohort analysis. Eur Respir J. 2020; 56(4). DOI: 10.1183/13993003.01720-2020. View

Corbella L, Boan J, San-Juan R, Fernandez-Ruiz M, Carretero O, Lora D . Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022; 59(2):106517. DOI: 10.1016/j.ijantimicag.2021.106517. View

Chen J, Liang Q, Chen X, Wu J, Wu Y, Teng G . Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Infection. Infect Drug Resist. 2022; 15:655-667. PMC: 8887910. DOI: 10.2147/IDR.S350976. View

Paglicci L, Borgo V, Lanzarone N, Fabbiani M, Cassol C, Cusi M . Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients. Eur J Clin Microbiol Infect Dis. 2021; 40(6):1271-1282. PMC: 8139905. DOI: 10.1007/s10096-021-04153-1. View

Chambers D, Cherikh W, Goldfarb S, Hayes Jr D, Kucheryavaya A, Toll A . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018; 37(10):1169-1183. DOI: 10.1016/j.healun.2018.07.020. View

van den Bogaart L, Manuel O . Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach. Antibiotics (Basel). 2022; 11(5). PMC: 9137688. DOI: 10.3390/antibiotics11050612. View

10.

Grupper M, Sutherland C, Nicolau D . Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Antimicrob Agents Chemother. 2017; 61(10). PMC: 5610483. DOI: 10.1128/AAC.00875-17. View

11.

Dettori M, Riccardi N, Canetti D, Antonello R, Piana A, Palmieri A . Infections in lung transplanted patients: A review. Pulmonology. 2022; 30(3):287-304. DOI: 10.1016/j.pulmoe.2022.04.010. View

12.

Moller D, Schwartz Sorensen S, Perch M, Gustafsson F, Rezahosseini O, Knudsen A . Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. Clin Microbiol Infect. 2021; 28(3):391-397. DOI: 10.1016/j.cmi.2021.07.021. View

13.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

14.

Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L . Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant in Liver Transplantation Recipients. Infect Drug Resist. 2022; 14:5603-5612. PMC: 8710070. DOI: 10.2147/IDR.S342163. View

15.

Di Nardo M, Tikkanen J, Husain S, Singer L, Cypel M, Ferguson N . Postoperative Management of Lung Transplant Recipients in the Intensive Care Unit. Anesthesiology. 2021; 136(3):482-499. DOI: 10.1097/ALN.0000000000004054. View

16.

Chambers D, Perch M, Zuckermann A, Cherikh W, Harhay M, Hayes Jr D . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021; 40(10):1060-1072. PMC: 10285650. DOI: 10.1016/j.healun.2021.07.021. View

17.

Su J, Li C, Liu H, Lian Q, Chen A, You Z . The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients. Microbiol Spectr. 2022; 10(2):e0034421. PMC: 9045364. DOI: 10.1128/spectrum.00344-21. View

18.

Jorgensen S, Trinh T, Zasowski E, Lagnf A, Bhatia S, Melvin S . Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2020; 6(12):ofz522. PMC: 6934163. DOI: 10.1093/ofid/ofz522. View

19.

Van Delden C, Stampf S, Hirsch H, Manuel O, Meylan P, Cusini A . Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study. Clin Infect Dis. 2020; 71(7):e159-e169. PMC: 7583409. DOI: 10.1093/cid/ciz1113. View

20.

Aguado J, Silva J, Fernandez-Ruiz M, Cordero E, Fortun J, Gudiol C . Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2017; 32(1):36-57. DOI: 10.1016/j.trre.2017.07.001. View